MX2019008292A - Composiciones probioticas y usos de las mismas. - Google Patents

Composiciones probioticas y usos de las mismas.

Info

Publication number
MX2019008292A
MX2019008292A MX2019008292A MX2019008292A MX2019008292A MX 2019008292 A MX2019008292 A MX 2019008292A MX 2019008292 A MX2019008292 A MX 2019008292A MX 2019008292 A MX2019008292 A MX 2019008292A MX 2019008292 A MX2019008292 A MX 2019008292A
Authority
MX
Mexico
Prior art keywords
lactobacillus
probiotic compositions
dsm
prevention
treatment
Prior art date
Application number
MX2019008292A
Other languages
English (en)
Inventor
Lazou Ahrén Irini
AGARDH Daniel
Niklas Larsson Lars
Original Assignee
Probi Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1700542.2A external-priority patent/GB201700542D0/en
Priority claimed from GBGB1709731.2A external-priority patent/GB201709731D0/en
Application filed by Probi Ab filed Critical Probi Ab
Publication of MX2019008292A publication Critical patent/MX2019008292A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Abstract

La presente invención se refiere a al menos una cepa probiótica de Lactobacillus para su uso en un sujeto para la prevención y/o el tratamiento de la autoinmunidad de la enfermedad celiaca (AEC), o para su uso en prevención y/o tratamiento de la enfermedad celíaca (CD).Una composición preferida para su uso de acuerdo con la invención es una composición que comprende una combinación de Lactobacillus paracasei y Lactobacillus plantarum, especialmente L. paracasei 8700:2 (DSM 13434) en combinación con L. plantarum HEAL 9 (DSM 15312).
MX2019008292A 2017-01-12 2018-01-12 Composiciones probioticas y usos de las mismas. MX2019008292A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1700542.2A GB201700542D0 (en) 2017-01-12 2017-01-12 Probiotic compositions and uses thereof
GBGB1709731.2A GB201709731D0 (en) 2017-06-19 2017-06-19 Probiotic compositions and uses thereof
PCT/EP2018/050789 WO2018130667A1 (en) 2017-01-12 2018-01-12 Probiotic compositions and uses thereof

Publications (1)

Publication Number Publication Date
MX2019008292A true MX2019008292A (es) 2019-09-16

Family

ID=61386800

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008292A MX2019008292A (es) 2017-01-12 2018-01-12 Composiciones probioticas y usos de las mismas.

Country Status (14)

Country Link
US (1) US11166993B2 (es)
EP (1) EP3568144A1 (es)
JP (1) JP7089523B2 (es)
KR (1) KR102500496B1 (es)
CN (1) CN110177561B (es)
AU (1) AU2018207946A1 (es)
BR (1) BR112019014418A2 (es)
CA (1) CA3049624A1 (es)
CL (1) CL2019001938A1 (es)
MX (1) MX2019008292A (es)
MY (1) MY195253A (es)
PH (1) PH12019501629A1 (es)
RU (1) RU2763311C2 (es)
WO (1) WO2018130667A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076615A2 (en) * 2003-02-27 2004-09-10 Bioneer A/S Immunomodulating probiotic compounds
WO2006097949A1 (en) * 2005-03-16 2006-09-21 Actial Farmacêutica, Lda. Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough
WO2007040444A1 (en) * 2005-10-06 2007-04-12 Probi Ab Method, device and computer program product for diagnosing of at least one exhaust emission control unit
CN101384269B (zh) * 2005-10-06 2012-11-14 普罗比公司 乳酸杆菌用于治疗病毒感染的用途
WO2007108763A1 (en) * 2006-03-17 2007-09-27 Probac Ab Use of lactobacillus strains for promoting immunotolerance in autoimmune disease
WO2007108764A2 (en) 2006-03-17 2007-09-27 Probac Ab Thermostable lactobacillus strains
EP2977053B1 (en) 2008-11-30 2017-07-05 Immusant, Inc. Compositions and methods for treatment of celiac disease
EP2581461B1 (en) * 2011-10-14 2014-09-24 GenMont Biotech Incorporation Composition and use of lactobacillus paracasei strain GMNL-133 in treating atopic dermatitis or other allergic diseases
DK3351554T3 (da) 2012-06-18 2021-08-30 Heinz Co Brands H J Llc Glutenrelaterede forstyrrelser
PL2981274T3 (pl) * 2013-04-03 2020-12-28 Probi Ab Szczepy probiotyczne do stosowania w leczeniu lub zapobieganiu osteoporozie
PL3223837T3 (pl) * 2014-11-25 2020-06-01 Dsm Ip Assets B.V. Lactobacillus do zastosowania jako probiotyk

Also Published As

Publication number Publication date
CN110177561A (zh) 2019-08-27
RU2763311C2 (ru) 2021-12-28
JP7089523B2 (ja) 2022-06-22
CL2019001938A1 (es) 2019-09-27
KR20190104568A (ko) 2019-09-10
AU2018207946A1 (en) 2019-07-25
WO2018130667A1 (en) 2018-07-19
PH12019501629A1 (en) 2020-06-01
US11166993B2 (en) 2021-11-09
MY195253A (en) 2023-01-11
US20190358275A1 (en) 2019-11-28
EP3568144A1 (en) 2019-11-20
CN110177561B (zh) 2023-09-12
JP2020513780A (ja) 2020-05-21
BR112019014418A2 (pt) 2020-04-14
RU2019121145A3 (es) 2021-04-26
RU2019121145A (ru) 2021-02-12
CA3049624A1 (en) 2018-07-19
KR102500496B1 (ko) 2023-02-16

Similar Documents

Publication Publication Date Title
EA202091389A1 (ru) Композиция на основе пробиотиков и её применение
MY160508A (en) Lactobacillus plantarum strains as hypocholesterolemic agents
PH12018550110A1 (en) Novel probiotic bacterial strain of lactobacillus plantarum and compositions and uses thereof in the treatment of inflammation
EP4086336A4 (en) STRAIN OF LACTOBACILLUS PLANTARUM, AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF METABOLIC DISEASES CONTAINING SAME
NZ777234A (en) Compositions comprising bacterial strains
WO2016086210A8 (en) Probiotic and prebiotic compositions, and methods of use thereof for treatment and prevention of graft versus host disease
MX2016014807A (es) Singenes de alfa(1,2)fucosiltransferasa para su utilizacion en la produccion de oligosacaridos fucosilados.
RU2015147106A (ru) Пробиотические штаммы для применения в лечении или профилактике остеопороза
MY161495A (en) Virus like particle compositions and methods of use
MX2020013439A (es) Composiciones probioticas y usos de las mismas.
PT2173196E (pt) Uso de probi?ticos e fibras para a diarreia
MX2021009398A (es) Composiciones probioticas que comprenden cepas de lactobacillus reuteri y metodos de uso.
NZ758787A (en) Beverage compositions containing bacillus coagulans mtcc 5856
EP4086335A4 (en) LACTOBACILLUS FERMENTUM STRAIN, AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF METABOLIC DISEASES, INCLUDING THE SAME
MX2016014991A (es) Composiciones que contienen acido borico y una mezcla de lactobacilos.
WO2020091179A3 (ko) 프로바이오틱스를 유효 성분으로 포함하는 이차성 골다공증의 예방 또는 치료용 조성물
MX2018002093A (es) Composicion y metodo para el tratamiento y profilaxis de infeccion e inflamacion intestinal.
MX2017015674A (es) Suplemento dietetico.
MX2021012676A (es) Composiciones probioticas y usos de las mismas.
GEP20207089B (en) Histamine-producing bacterial strains and their use in cancer
EP3757207A4 (en) Bifidobacterium lungum rapo strain for alleviation, prevention, or treatment of rheumatoid arthritis and composition comprising same
WO2020091180A3 (ko) 프로바이오틱스를 유효 성분으로 포함하는 이차성 골다공증의 예방 또는 치료용 조성물
MX2020007946A (es) Un producto de combinacion para profilaxis y tratamiento de sindrome de intestino irritable.
PH12019501629A1 (en) Probiotic compositions and uses therof
WO2020231031A3 (ko) 락토바실러스 아시도필루스를 포함하는 갱년기 여성의 근관절통, 두통, 또는 질 건조증의 예방, 개선, 또는 치료용 조성물